Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CERO 
CERo Therapeutics Holdings, Inc. Common Stock (CERO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/03/2025: CERO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.5
1 Year Target Price $22.5
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.99% | Avg. Invested days 60 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.18M USD | Price to earnings Ratio - | 1Y Target Price 22.5 |
Price to earnings Ratio - | 1Y Target Price 22.5 | ||
Volume (30-day avg) 2 | Beta 0.32 | 52 Weeks Range 0.06 - 896.00 | Updated Date 11/4/2025 |
52 Weeks Range 0.06 - 896.00 | Updated Date 11/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.09 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -156.89% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12421490 | Price to Sales(TTM) - |
Enterprise Value 12421490 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 1865147 | Shares Floating 1179980 |
Shares Outstanding 1865147 | Shares Floating 1179980 | ||
Percent Insiders 1.73 | Percent Institutions 16.63 |
Upturn AI SWOT
CERo Therapeutics Holdings, Inc. Common Stock
Company Overview
History and Background
CERo Therapeutics Holdings, Inc. is a biotechnology company focused on developing novel immunotherapies for cancer. Founded to advance potentially curative treatments for various cancers.
Core Business Areas
- Immuno-oncology Drug Development: Focuses on discovering and developing novel immunotherapies targeting various cancers. This includes research, preclinical studies, and clinical trials.
Leadership and Structure
Information about CERo Therapeutics Holdings, Inc.'s leadership team and organizational structure is not readily available in detail. Generally, biotech companies have a CEO, CSO, and CMO leading research and clinical development.
Top Products and Market Share
Key Offerings
- CER-123 (Preclinical): A novel immunotherapy candidate in preclinical development. Specific market share data is unavailable as it's not yet commercialized. Competitors include major pharmaceutical companies developing immunotherapies such as Merck (MRK), Bristol Myers Squibb (BMY), and Roche (RHHBY).
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing significant growth, driven by the increasing prevalence of cancer and the promise of more effective and targeted therapies compared to traditional treatments. It's highly competitive and innovative.
Positioning
CERo Therapeutics Holdings, Inc. is positioned as an early-stage biotechnology company focused on innovative immuno-oncology approaches. Its competitive advantage, if any, lies in the uniqueness and efficacy of its drug candidates, if successful in clinical trials.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of dollars. CERo Therapeutics Holdings, Inc.'s position depends on its success in developing and commercializing its pipeline products. As a pre-clinical stage company, they are very early in capturing TAM
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Experienced scientific team (assumed based on biotech focus)
- Potential for high-impact cancer treatment
Weaknesses
- Early stage of development (preclinical)
- Limited financial resources compared to large pharma
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Advancements in immunotherapy technologies
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Financing risks
Competitors and Market Share
Key Competitors
- MRK
- BMY
- RHHBY
Competitive Landscape
CERo Therapeutics Holdings, Inc. faces intense competition from established pharmaceutical companies with greater resources and broader pipelines. Its success depends on the differentiation and efficacy of its novel therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is hard to determine, company is likely relatively new.
Future Projections: Future projections are highly speculative and dependent on the success of their drug development programs. Analyst estimates are not publicly available.
Recent Initiatives: Recent Initiatives are difficult to assess without company communications or public filings.
Summary
CERo Therapeutics Holdings, Inc. is an early-stage biotechnology company with a focus on immuno-oncology. While the company has the potential to develop innovative cancer therapies, it faces significant risks associated with drug development, including clinical trial failures and competition from larger companies. Their key strength lies in their novel approach, but weaknesses include limited resources. Success depends on positive clinical trial results and strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website (limited info available)
- SEC Filings (if available)
- Market Research Reports (immuno-oncology market)
- General Biotech Industry News
Disclaimers:
This analysis is based on limited publicly available information and assumptions. The biotechnology industry is inherently risky, and investment decisions should be made with caution and after consulting with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CERo Therapeutics Holdings, Inc. Common Stock
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2024-02-15 | CEO & Chair Mr. Christopher B. Ehrlich M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.cero.bio |
Full time employees 8 | Website https://www.cero.bio | ||
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.